The long-term objective of this research is to elucidate the mechanisms of chemical carcinogenesis in the human uroepithelium with the hope that this knowledge can be used to develop improved strategies to prevent, diagnose, or treat human bladder cancers. The immediate goal of the proposed studies is to analyze the role of alternations in ras cellular proto-oncogenes in transformation in vitro of human uroepithelial cells (HUC), and to relate these findings to multi-stage bladder cancers in vivo. The rationale for studying ras genes in haman bladder cancers is based on the following. (1) Activated ras cellular proto-oncogenes have been idenfified in human bladder cancers. (2) ras proto- oncogenes are activiated by point mutations in rodent cells transformed in vivo and in vitro by some chemical carcinogens including NMU and MCA, which cause bladder cancer in rodents.
The specific aims are: (1) to determine if transformants of HUC generated in vitro by treatment of HUC with bladder carcinogens (e.g., NMU, MCA, and arylamine compounds) have alterations in ras genes which can be detected by molecular genetic analysis; (2) to determine if transfection in vitro of HUC or superficial transitional carcinoma cells by the mutated c-Ha-ras-1 gene from the EJ/T24 human bladder cancer line alone, or together with an oncogene that immortalizes cells (e.g., c-myc), results in neoplastic transformation; and (3) to determine the nature and frequency of alterations in ras genes in metastases of human bladder cancers. The significance of these studies is that they directly address critical questions concerning the etiological role of alterations in ras genes in human bladder carcinogenesis using suitable carcinogens and a relevant human epithelial cell culture system.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Research Project (R01)
Project #
Application #
Study Section
Chemical Pathology Study Section (CPA)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of Wisconsin Madison
Schools of Medicine
United States
Zip Code
Sarkar, S; Julicher, K P; Burger, M S et al. (2000) Different combinations of genetic/epigenetic alterations inactivate the p53 and pRb pathways in invasive human bladder cancers. Cancer Res 60:3862-71
Cuthill, S; Agarwal, P; Sarkar, S et al. (1999) Dominant genetic alterations in immortalization: role for 20q gain. Genes Chromosomes Cancer 26:304-11
Vieten, L; Belair, C D; Savelieva, L et al. (1998) Minimal deletion of 3p13-->14.2 associated with immortalization of human uroepithelial cells. Genes Chromosomes Cancer 21:39-48
Yeager, T R; Reznikoff, C A (1998) Methotrexate resistance in human uroepithelial cells with p53 alterations. J Urol 159:581-5
Savelieva, E; Belair, C D; Newton, M A et al. (1997) 20q gain associates with immortalization: 20q13.2 amplification correlates with genome instability in human papillomavirus 16 E7 transformed human uroepithelial cells. Oncogene 14:551-60
Belair, C D; Yeager, T R; Lopez, P M et al. (1997) Telomerase activity: a biomarker of cell proliferation, not malignant transformation. Proc Natl Acad Sci U S A 94:13677-82
Reznikoff, C A; Belair, C D; Yeager, T R et al. (1996) A molecular genetic model of human bladder cancer pathogenesis. Semin Oncol 23:571-84
Reznikoff, C A; Yeager, T R; Belair, C D et al. (1996) Elevated p16 at senescence and loss of p16 at immortalization in human papillomavirus 16 E6, but not E7, transformed human uroepithelial cells. Cancer Res 56:2886-90
Reznikoff, C A; Belair, C; Savelieva, E et al. (1994) Long-term genome stability and minimal genotypic and phenotypic alterations in HPV16 E7-, but not E6-, immortalized human uroepithelial cells. Genes Dev 8:2227-40
Reznikoff, C A; Kao, C; Messing, E M et al. (1993) A molecular genetic model of human bladder carcinogenesis. Semin Cancer Biol 4:143-52

Showing the most recent 10 out of 21 publications